| 培美曲赛单药与培美曲赛联合奥沙利铂用于IV期肺腺癌挽救性治疗的比较 |
| |
| 引用本文： | 刘友如,江银铃,高志强,王向迎,韩宝惠,姜丽岩.培美曲赛单药与培美曲赛联合奥沙利铂用于IV期肺腺癌挽救性治疗的比较[J].中国肺癌杂志,2011,14(9):704-709. |
| |
| 作者姓名： | 刘友如 江银铃 高志强 王向迎 韩宝惠 姜丽岩 |
| |
| 作者单位： | 上海交通大学附属胸科医院肺内科,上海,200030 |
| |
| 摘 要： | 背景与目的目前肺癌挽救性治疗尚无标准方案。本研究旨在比较培美曲赛单药与培美曲赛联合奥沙利铂挽救性治疗IV期肺腺癌患者的疗效及安全性,为联合化疗提供依据。方法 2009年1月-2011年2月共83例体能状态评分(performance status,PS)为0分-2分的IV期肺腺癌患者分别接受培美曲赛(单药组47例)和培美曲赛联合奥沙利铂(联合组36例)挽救性治疗,观察两组近期疗效和毒性反应并进行比较。结果 81例患者纳入最终分析。单药组与联合组中位无进展生存时间(progression-free survival,PFS)分别为3.6个月vs4.1个月(P=0.268),客观反应率(objective response rate,ORR)和疾病控制率(disease control rate,DCR)分别为6.5%vs20%(P=0.092)和56.5%vs65.7%(P=0.493)。单药组与联合组血液毒性及胃肠道反应发生率分别为33.9%vs47.2%(P=0.460)和21.2%vs25.0%(P=0.213)。结论培美曲赛联合奥沙利铂挽救性治疗PS评分较好的IV期肺腺癌患者耐受性良好,与培美曲赛单药相比显示出较高的缓解率,但未明显增加患者的PFS。
|
| 关 键 词： | 肺肿瘤 培美曲赛 奥沙利铂 吉非替尼 厄洛替尼 |
Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy in Stage IV Lung Adenocarcinoma |
| |
| Youru LIU,Yuiling JIANG,Zhigiang GAO,Xiangying WANG,Baohui HAN,Liyan JIANG.Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy in Stage IV Lung Adenocarcinoma[J].Chinese Journal of Lung Cancer,2011,14(9):704-709. |
| |
| Authors: | Youru LIU Yuiling JIANG Zhigiang GAO Xiangying WANG Baohui HAN Liyan JIANG |
| |
| Institution: | Youru LIU,Yinling JIANG,Zhiqiang GAO,Xiangying WANG,Baohui HAN,Liyan JIANG Department of Pulmonary,Chest Hospital Affiliated to Shanghai Jiaotong University,Shanghai 200030,China |
| |
| Abstract: | Background and objective At present,there is no standard salvage treatment strategies for lung cancer.The aim of this study is to compare the efficacies and safeties of pemetrexed alone with pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma to provide evidences for combination therapy.Methods From January 2009 to February 2011,83 patients with stage IV lung adenocarcinoma received pemetrexed alone (single agent arm,n=47) or pemetrexed combined with oxaliplatin (combinat... |
| |
| Keywords: | Lung neoplasms Pemetrexed Oxaliplatin Gefitinib Erlotinib |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
